Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib plus chemotherapy/chemoimmunotherapy in pediatric and young adult patients with relapsed/refractory solid tumors and neuroblastoma
2023-506778-11-00Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of abemaciclib in Nonhematologic neoplasms and neuroblastoma (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Dose Limiting Toxicity (DLT), Maximum Tolerated Doses (MTD) and 1 more. Started Apr 2024; status: completed.
02
Drugs
abemaciclib
03
Conditions
Nonhematologic neoplasmsneuroblastoma
Beyond the preview
Go deeper on 2023-506778-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506778-11-00.